Learn about the link between primary biliary cholangitis (PBC) and fatigue, and get tips to restore energy and improve your daily life.

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024 Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.

Please provide your email address to receive an email when new articles are posted on . Results presented at The Liver Meeting demonstrated volixibat (Mirum Pharmaceuticals) significantly improved ...

Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not appropriately diagnosed and treated. "PBC is one of those liver diseases where ...

GSK’s Lynavoy receives US FDA approval for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Saturday, March 21, 2026, 11:00 Hrs [IST] GSK plc announ ...

PARIS, FRANCE, 15 November 2024 Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data for Iqirvo ® (elafibranor 80 mg tablets) from an interim analysis of the ongoing open-label ...